9 pending office actions • 6 clients
| Client (Assignee) | Pending OAs |
|---|---|
| BAUSCH HEALTH IRELAND LIMITED | 3 |
| Salix Pharmaceuticals, Inc. | 2 |
| Durect Corporation | 1 |
| The United States Department of Veterans Affairs | 1 |
| Durect Corporation | 1 |
| BAUSCH HEALTH IRELAND LIMITED | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19299563 | Solid Dispersion Forms of Rifaximin | Salix Pharmaceuticals, Inc. | WEDDINGTON, KEVIN E | 1629 | Non-Final OA | Aug 14, 2025 |
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | Durect Corporation | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Dec 20, 2023 |
| 18241355 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Salix Pharmaceuticals, Inc. | SCHMITT, MICHAEL J | 1629 | Non-Final OA | Sep 01, 2023 |
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | BAUSCH HEALTH IRELAND LIMITED | MOU, LIYUAN | 1628 | Non-Final OA | Apr 28, 2023 |
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | The United States Department of Veterans Affairs | RODRIGUEZ, RAYNA B | 1628 | Non-Final OA | Dec 06, 2022 |
| 17924101 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) | Durect Corporation | NOTTINGHAM, KYLE GREGORY | 1621 | Final Rejection | Nov 08, 2022 |
| 17965394 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | BAUSCH HEALTH IRELAND LIMITED | KOSTURKO, GEORGE W | 1621 | Non-Final OA | Oct 13, 2022 |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | BAUSCH HEALTH IRELAND LIMITED | ROBINSON, MIKHAIL O'DONNEL | 1627 | Final Rejection | Sep 23, 2022 |
| 17747938 | POLYMERIC EMULSION DELIVERY SYSTEMS | BAUSCH HEALTH IRELAND LIMITED | VALENROD, YEVGENY | 1628 | Final Rejection | May 18, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial